Current status of testosterone replacement therapy in men
- PMID: 10333822
- DOI: 10.1001/archfami.8.3.257
Current status of testosterone replacement therapy in men
Abstract
Testosterone plays an essential role in the development of the normal male and in the maintenance of many male characteristics, including muscle mass and strength, bone mass, libido, potency, and spermatogenesis. Androgen deficiency occurs with disorders that damage the testes, including traumatic or surgical castration (primary testicular failure) or disorders in which the gonadotropin stimulation of the testes is reduced (hypogonadotropic hypogonadism). The clinical manifestations of androgen deficiency depend on the age at onset and the severity and duration of the deficiency. In adult males, these manifestations may include reduced body hair, decreased muscle mass and strength, increased fat mass, decreased hematocrit, decreased libido, erectile dysfunction, infertility, osteoporosis, and depressed mood. The forms of androgen replacement currently available in the United States are intramuscular depot injections of testosterone esters, oral tablets of testosterone derivatives, and transdermal patches. For most patients, androgen replacement therapy with testosterone is a safe, effective treatment for testosterone deficiency.
Comment in
-
Testosterone in aging men.Arch Fam Med. 2000 Mar;9(3):221. doi: 10.1001/archfami.9.3.221. Arch Fam Med. 2000. PMID: 10728106 No abstract available.
Similar articles
-
Testosterone replacement therapy in male hypogonadism.J Endocrinol Invest. 2003 May;26(5):481-9. doi: 10.1007/BF03345206. J Endocrinol Invest. 2003. PMID: 12906378 Review.
-
A practical guide to male hypogonadism in the primary care setting.Int J Clin Pract. 2010 May;64(6):682-96. doi: 10.1111/j.1742-1241.2010.02355.x. Int J Clin Pract. 2010. PMID: 20518947 Free PMC article. Review.
-
Hormonal therapy of male hypogonadism.Endocrinol Metab Clin North Am. 1994 Dec;23(4):857-75. Endocrinol Metab Clin North Am. 1994. PMID: 7705324 Review.
-
Male acquired hypogonadotropic hypogonadism: diagnosis and treatment.Ann Endocrinol (Paris). 2012 Apr;73(2):141-6. doi: 10.1016/j.ando.2012.03.040. Epub 2012 Apr 25. Ann Endocrinol (Paris). 2012. PMID: 22541999 Review.
-
Hormone substitution in male hypogonadism.Mol Cell Endocrinol. 2000 Mar 30;161(1-2):73-88. doi: 10.1016/s0303-7207(99)00227-0. Mol Cell Endocrinol. 2000. PMID: 10773395 Review.
Cited by
-
Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study.Osteoporos Int. 2005 Jul;16(7):791-8. doi: 10.1007/s00198-004-1754-7. Epub 2004 Oct 16. Osteoporos Int. 2005. PMID: 15502960
-
Effect of testosterone undecanoate on hematological profiles, blood lipid and viscosity and plasma testosterone level in castrated rabbits.Can Urol Assoc J. 2013 Mar-Apr;7(3-4):E221-5. doi: 10.5489/cuaj.507. Can Urol Assoc J. 2013. PMID: 23671530 Free PMC article.
-
Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides.Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1202-5. doi: 10.1073/pnas.97.3.1202. Proc Natl Acad Sci U S A. 2000. PMID: 10655508 Free PMC article.